Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL
PubMed Full text in PMC Similar studies SRA Run Selector
Illumina HiSeq 4000 (Homo sapiens)
ATAC-seq for patient CLL9 during Ibrutinib treatment
SRA Run Selector
ATAC-seq for patient CLL9 before Ibrutinib treatment
ATAC-seq for patient CLL7 during Ibrutinib treatment
ATAC-seq for patient CLL7 before Ibrutinib treatment
ATAC-seq for patient CLL6 during Ibrutinib treatment
ATAC-seq for patient CLL6 before Ibrutinib treatment
ATAC-seq for patient CLL5 before Ibrutinib treatment
ATAC-seq for patient CLL5 during Ibrutinib treatment
ATAC-seq for patient CLL4 during Ibrutinib treatment
ATAC-seq for patient CLL4 before Ibrutinib treatment
ATAC-seq for patient CLL3 during Ibrutinib treatment
ATAC-seq for patient CLL3 before Ibrutinib treatment
ATAC-seq for patient CLL21 before Ibrutinib treatment
ATAC-seq for patient CLL21 during Ibrutinib treatment
ATAC-seq for patient CLL20 during Ibrutinib treatment
ATAC-seq for patient CLL20 before Ibrutinib treatment
ATAC-seq for patient CLL2 before Ibrutinib treatment
ATAC-seq for patient CLL2 during Ibrutinib treatment
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on